Attributes | Values |
---|
rdf:type
| |
Description
| - Anticancer agents specifically targeting cancer cell mitochondria are referred to as 'mitocans'. They act by destabilising mitochondria, unleashing their apoptogenic potential, resulting in death of malignant cells and suppression of tumour growth. At least some mitocans are selective for cancer cells, and these are represented by redox-silent vitamin E analogues, epitomised by α-tocopheryl succinate (α-TOS). This compound has proven itself in pre-clinical models to be an efficient anti-cancer agent, targeting complex II of the respiratory chain to displace ubiquinone binding. We propose that disrupting the electron flow of mitochondrial complex II results in generation of superoxide, triggering mitochondrial destabilisation and initiation of apoptosis. Moreover, α-TOS is selective for cancer cells with their reduced antioxidant defenses and lower esterase activity than the non-malignant counterparts. Here we discuss the emerging significance of mitocans, as exemplified by α-TOS.
- Anticancer agents specifically targeting cancer cell mitochondria are referred to as 'mitocans'. They act by destabilising mitochondria, unleashing their apoptogenic potential, resulting in death of malignant cells and suppression of tumour growth. At least some mitocans are selective for cancer cells, and these are represented by redox-silent vitamin E analogues, epitomised by α-tocopheryl succinate (α-TOS). This compound has proven itself in pre-clinical models to be an efficient anti-cancer agent, targeting complex II of the respiratory chain to displace ubiquinone binding. We propose that disrupting the electron flow of mitochondrial complex II results in generation of superoxide, triggering mitochondrial destabilisation and initiation of apoptosis. Moreover, α-TOS is selective for cancer cells with their reduced antioxidant defenses and lower esterase activity than the non-malignant counterparts. Here we discuss the emerging significance of mitocans, as exemplified by α-TOS. (en)
- Protirakovinné látky, které specificky zasahují mitochondrie rakovinných buněk jsou označovány jako „mitokany“. Účinkují tím, že destabilizují mitochondrie a uvolňují jejich apoptogenní potenciál, což vede ke smrti maligních buněk a potlačení růstu nádorů. Přinejmenším některé mitokany jsou selektivní pro rakovinné buňky. Takové jsou reprezentovány redox-neaktivními analogy vitaminu E (například α-tokoferylsukcinátem, α-TOS). Bylo prokázáno, že α-TOS je účinná protirakovinná látka v preklinických modelech, která vytěsňuje ubichinon z vazby v komplexu II respiračního řetězce. Navrhujeme, že přerušení toku elektronů v mitochondriálním komplexu II vede ke vzniku superoxidu, což způsobí mitochondriální destabilizaci a iniciaci apoptózy. Nadto, α-TOS je selektivní pro rakovinné buňky s jejich sníženou antioxidační obranou a nižší esterázovou aktivitou ve srovnání s nemaligními buňkami. Zde na příkladu α-TOS diskutujeme vzrůstající význam mitokanů (cs)
|
Title
| - Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II
- Mitokany jako protirakovinné látky zasahující mitochondrie: studie s analogy vitaminu E, inhibitory komplexu II (cs)
- Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II (en)
|
skos:prefLabel
| - Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II
- Mitokany jako protirakovinné látky zasahující mitochondrie: studie s analogy vitaminu E, inhibitory komplexu II (cs)
- Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II (en)
|
skos:notation
| - RIV/68378050:_____/07:00096337!RIV08-AV0-68378050
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| - Z(AV0Z50520514), Z(AV0Z50520701), Z(MZE0002716201)
|
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/68378050:_____/07:00096337
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - mitocans; mitochondria; complex II (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Journal of Bioenergetics and Biomembranes
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Dyason, J. C.
- Neužil, Jiří
- Ralph, S. J.
- Dong, L. F.
- Freeman, R.
- Procházka, L.
- Wang, X. F.
- Scheffler, I.
|
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |